192 related articles for article (PubMed ID: 36115256)
1. Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study.
Durmuş ET; Atmaca A; Kefeli M; Çalışkan S; Mete O; Aslan K; Fidan M; Çolak R; Durmuş B
Growth Horm IGF Res; 2022 Dec; 67():101502. PubMed ID: 36115256
[TBL] [Abstract][Full Text] [Related]
2. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.
Potorac I; Petrossians P; Daly AF; Alexopoulou O; Borot S; Sahnoun-Fathallah M; Castinetti F; Devuyst F; Jaffrain-Rea ML; Briet C; Luca F; Lapoirie M; Zoicas F; Simoneau I; Diallo AM; Muhammad A; Kelestimur F; Nazzari E; Centeno RG; Webb SM; Nunes ML; Hana V; Pascal-Vigneron V; Ilovayskaya I; Nasybullina F; Achir S; Ferone D; Neggers SJ; Delemer B; Petit JM; Schöfl C; Raverot G; Goichot B; Rodien P; Corvilain B; Brue T; Schillo F; Tshibanda L; Maiter D; Bonneville JF; Beckers A
Endocr Relat Cancer; 2016 Nov; 23(11):871-881. PubMed ID: 27649724
[TBL] [Abstract][Full Text] [Related]
3. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly.
Bhayana S; Booth GL; Asa SL; Kovacs K; Ezzat S
J Clin Endocrinol Metab; 2005 Nov; 90(11):6290-5. PubMed ID: 16118335
[TBL] [Abstract][Full Text] [Related]
4. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
5. Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.
Yamamoto R; Robert Shima K; Igawa H; Kaikoi Y; Sasagawa Y; Hayashi Y; Inoshita N; Fukuoka H; Takahashi Y; Takamura T
Endocr J; 2018 Oct; 65(10):1061-1067. PubMed ID: 30078825
[TBL] [Abstract][Full Text] [Related]
6. Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly.
Tomasik A; Stelmachowska-Banaś M; Maksymowicz M; Czajka-Oraniec I; Raczkiewicz D; Zieliński G; Kunicki J; Zgliczyński W
Front Endocrinol (Lausanne); 2022; 13():957301. PubMed ID: 36187106
[TBL] [Abstract][Full Text] [Related]
7. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
Petrossians P; Borges-Martins L; Espinoza C; Daly A; Betea D; Valdes-Socin H; Stevenaert A; Chanson P; Beckers A
Eur J Endocrinol; 2005 Jan; 152(1):61-6. PubMed ID: 15762188
[TBL] [Abstract][Full Text] [Related]
8. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
[TBL] [Abstract][Full Text] [Related]
9. PREDICTIVE MARKERS FOR POSTSURGICAL MEDICAL MANAGEMENT OF ACROMEGALY: A SYSTEMATIC REVIEW AND CONSENSUS TREATMENT GUIDELINE.
Ezzat S; Caspar-Bell GM; Chik CL; Denis MC; Domingue MÈ; Imran SA; Johnson MD; Lochnan HA; Grégoire Nyomba BL; Prebtani A; Ridout R; Ramirez JAR; Van Uum S
Endocr Pract; 2019 Apr; 25(4):379-393. PubMed ID: 30657362
[No Abstract] [Full Text] [Related]
10. Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study.
Petersenn S; Houchard A; Sert C; Caron PJ;
Pituitary; 2020 Apr; 23(2):171-181. PubMed ID: 31879842
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.
Dogansen SC; Yalin GY; Tanrikulu S; Tekin S; Nizam N; Bilgic B; Sencer S; Yarman S
Pituitary; 2018 Aug; 21(4):347-354. PubMed ID: 29460202
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic strategies in somatotroph adenomas with extrasellar extension: role of the medical approach, a consensus study of the French Acromegaly Registry].
Jaquet P; Cortet-Rudelli Ch; Sassolas G; Morange-Ramos I; Chanson P; Brue T; Andrieu JM; Beckers A; Bertherat J; Borson-Chazot F; Brassier G; Caron P; Cogne M; Cottier JP; Delemer B; Dufour H; Enjalbert A; Figarella-Branger D; Gaillard R; Gueydan M; Jan M; Kuhn JM; Raingeard I; Regis J; Roger P; Rohmer V; Sadoul JL; Saveanu A; Tabarin A; Travers N; Trouillas J;
Ann Endocrinol (Paris); 2003 Dec; 64(6):434-41. PubMed ID: 15067248
[TBL] [Abstract][Full Text] [Related]
13. Correlation between tumor invasion and somatostatin receptor subtypes in acromegaly.
Zhang S; Yao S; Chen J; Akter F; Yang J; Zhu D; Zeng A; Chen W; Mao Z; Zhu Y; Wang H
J Neurosurg; 2024 Apr; 140(4):1019-1028. PubMed ID: 37856412
[TBL] [Abstract][Full Text] [Related]
14. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.
Sherlock M; Fernandez-Rodriguez E; Alonso AA; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
J Clin Endocrinol Metab; 2009 Apr; 94(4):1255-63. PubMed ID: 19158203
[TBL] [Abstract][Full Text] [Related]
15. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly.
Heck A; Ringstad G; Fougner SL; Casar-Borota O; Nome T; Ramm-Pettersen J; Bollerslev J
Clin Endocrinol (Oxf); 2012 Jul; 77(1):72-8. PubMed ID: 22066905
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure.
Puig-Domingo M; Resmini E; Gomez-Anson B; Nicolau J; Mora M; Palomera E; Martí C; Halperin I; Webb SM
J Clin Endocrinol Metab; 2010 Nov; 95(11):4973-8. PubMed ID: 20739382
[TBL] [Abstract][Full Text] [Related]
17. Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response.
Helseth R; Carlsen SM; Bollerslev J; Svartberg J; Øksnes M; Skeie S; Fougner SL
Endocrine; 2016 Feb; 51(2):298-307. PubMed ID: 26179177
[TBL] [Abstract][Full Text] [Related]
18. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy.
Ayuk J; Stewart SE; Stewart PM; Sheppard MC;
Clin Endocrinol (Oxf); 2004 Mar; 60(3):375-81. PubMed ID: 15009004
[TBL] [Abstract][Full Text] [Related]
20. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.
Schwyzer L; Starke RM; Jane JA; Oldfield EH
J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]